Proteasome inhibitors – molecular basis and current perspectives in multiple myeloma

Inhibition of proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple myeloma (MM), a plasma cell malignancy. First-in-class agent, bortezomib, has demonstrated great positive therapeutic efficacy in MM...

Full description

Saved in:
Bibliographic Details
Published in:J Cell Mol Med
Main Authors: Kubiczkova, Lenka, Pour, Ludek, Sedlarikova, Lenka, Hajek, Roman, Sevcikova, Sabina
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2014
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4508135/
https://ncbi.nlm.nih.gov/pubmed/24712303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.12279
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items